Carl Icahn
Carl Icahn is a billionaire financier, ranking #18 on the 2007 Forbes 400 list with an estimated net worth of $14.5 billion.
Icahn built a name for himself in the 1980s as a corporate raider. After keeping quite for years, Icahn made a major comeback as a 'activist investor'. An activist investor agitates companies for changes, including buyouts, share buybacks, and dividend increases.
Icahn has successfully pushed for changes at Time Warner (NYSE: TWX) and Temple-Inland (NYSE: TIN), among others. Icahn won board seats at Motorola (NYSE: MOT) after first failing.
In 2007, Icahn's activism successfully pushed biotech company MedImmune into a sales agreement with AstraZeneca (NYSE: AZN). Icahn is also involved with biotech company Imclone Systems (Nasdaq: IMCL), where he is Chairman of the Board.
In early, 2008 Icahn activist target BEA Systems (Nasdaq: BEAS) was sold to Oracle (Nasdaq: ORCL). Icahn held a 13% stake in BEA.
Icahn is also involved with developments at Biogen Idec (Nasdaq: BIIB) and WCI Communities (NYSE: WCI), which both unsuccessfully explored sales. WCI rejected a $22 per share takeover offer from Icahn in early 2007, only to see its stock plummet on the housing slowdown.
In 2008, Icahn targeted Yahoo! (Nasdaq: YHOO) after the Internet company failed to work out an acceptable merger agreement with Microsoft (Nasdaq: MSFT) Microsoft walked away from its bid for Yahoo! after months of bickering.
-
Vivus (VVUS) Sees Upside on Icahn Connection
-
Top 10 News Items for 03/25 - 03/28: S&P 500 Hits New Record High; Q4 U.S. GDP Growth Ebbs; Investors Flock Dell
-
Carl Icahn Liquidates Biogen Idec (BIIB), Chesapeake Energy (CHK); Targets Oshkosh (OSK), Forest Labs (FRX) and Commercial Metals (CMC)
-
Icahn Capital Lowers Stake in Biogen Idec, Inc. (BIIB) to 3.4%
-
Call Icahn Dumps Over 2 Million Biogen Idec (BIIB) Shares
-
Carl Icahn Sells Biogen Idec (BIIB) Shares
-
Icahn's Icahn Capital Shows New Stake in Amgen (AMGN), Clorox (CLX) and Southern Union (NYSE: SUG); Raises Dynegy (DYN), Lowers Chesapeake (CHK)
-
Icahn Gives Seal of Approval to Biogen (BIIB); Skips Director Nomination
-
Icahn Hangs on to Pharmas, Makes Housing Play, Increases Lions Gate Holding in Recent 13F (MOT, MAS, HAIN, More...)
-
Carl Icahn Shows New Stakes In Energy Names and a Gun Maker (APC, NRG, SWHC)
-
Wall Street Hubbub 7/21: Traders Nervous Ahead NFLX/BIDU Results, Dimon & Blankfein Not Welcome at FinReg Signing, Bernanke Set to Testify, BIIB/LLL/DTG In the Rumor Mill
-
Biogen (BIIB) to Name George Scangos as New CEO -Reuters
-
Icahn Gets Another Seat on Biogen (BIIB) Board
-
Biogen (BIIB) Appoint Dr.'s Eric Rowinsky and Stephen Sherwin to Board
-
Biogen Idec (BIIB) Up On Renewed Takeover Speculation
-
Icahn Seeks To Shake-Up Genzyme's (GENZ) Board
-
Carl Icahn Raises Stakes In Take-Two (TTWO) and Genzyme (GENZ), Slashes Stake in Yahoo! (YHOO)
-
Icahn Plans to Nominate Three To Biogen Idec (BIIB) Board
-
Standpoint Research Initiates Coverage on Biogen Idec (BIIB) with a Buy
-
Icahn's 13Fs Show No Major Changes (YHOO, MOT, BIIB, AMLN, LGF)
-
Sanofi-Aventis (SNY) On the Prowl For A Mega-Deal In the U.S.?
-
Icahn Says Future Is Big Pharma Will Buy Biotech (BIIB, AMLN)
-
Icahn's Group Reportedly To Get 2 of The 4 Biogen Idec (BIIB) Board Seats
-
Icahn To File Lawsuit To Stop Biogen Idec (BIIB) Vote
-
Biogen Idec (BIIB) Shareholder Meeting In Recess, Icahn Wants Vote Closed
-
RiskMetrics Supports Two From Icahn Slate For Biogen Idec (BIIB) Board
-
Biogen (BIIB) Advisors Recommend Not Voting for Icahn's Slate of Directors
-
Icahn Boosts Stake in American Railcar (ARII), Maintains Large Yahoo! (YHOO) and Motorola (MOT) Holdings
-
Carl Icahn Suggests Biogen (BIIB) Should Consider Splitting in Two -DJ
-
After-Hours Movers 4/16: TEL, DRYS, TPX, ICUI Higher; CYT, MGM, WRI, AMLN, BIIB Lower
-
Biogen Idec (BIIB) May volatility at 58; July at 51 into EPS and Icahn pressure
-
Biogen Idec (BIIB) Rises On Renewed Takeover Talk
-
Biogen (BIIB) Rejects Icahn's Proposals
-
Icahn Raises Stakes In AMLN, LGF, WMB, YHOO; Cuts Stakes in TIN, LEA
-
Baird Downgrades Biogen Idec (BIIB) On Tysabri, Not Buying Takeover Talk
-
Icahn Seeks To Add Four To Biogen Idec's (BIIB) Board
-
Icahn Down $60M on Healthcare Stocks This Week (AMLN, BIIB, CYBX, REGN, FOLD)
-
Icahn's Icahn Capital Bumps Stake in Motorola (MOT), Shows New Small Stake in Emisphere (EMIS)
-
Icahn Boosts Stake in Biogen Idec (BIIB) to 6% Following TYSABRI Sell-Off
-
StreetInsider.com Top 10 News Items 7/28-8/1: Merrill, ImClone, Biogen/Elan, More...
-
Biotech Takeover Buzz Hot and Heavy After ImClone Offer (ONXX, OSIP, BIIB, AMLN, XPNT, CYPB, ISPH)
-
Amylin Pharmaceuticals (AMLN) Could Be One To Watch On ImClone Bid
-
Biogen Idec (BIIB) Could Be One To Watch On ImClone Bid
-
Pre-Open Movers 7/21: Genentech (DNA) Higher on Bid for Roche; BofA (BAC) Up on Results
-
Carl Icahn Loses Proxy Battle At Biogen Idec (BIIB)-WSJ
-
Deutsche Bank Starts Biogen-IDEC (BIIB) at Hold
-
Pre-Open Movers 6/11: Agrium (AGU) Higher on Raised Guidance; AMERIGROUP (AGP) Down After Suspending Guidance
-
Reports Icahn Offered To Acquire Biogen Idec (BIIB) For As Much as $82/Share in Fall 2007
-
Judge Rules Biogen (BIIB) Must Give Icahn Access to Sales Records -Bloomberg
-
Icahn's Icahn Capital Boosts Stake in Biogen (BIIB) to Nearly 10M Shares
